2023
Personality Changes and Staring Spells in a 12-Year-Old Child: A Case Report Incorporating ChatGPT, a Natural Language Processing Tool Driven by Artificial Intelligence (AI)
Puthenpura V, Nadkarni S, DiLuna M, Hieftje K, Marks A. Personality Changes and Staring Spells in a 12-Year-Old Child: A Case Report Incorporating ChatGPT, a Natural Language Processing Tool Driven by Artificial Intelligence (AI). Cureus 2023, 15: e36408. PMID: 37090271, PMCID: PMC10115215, DOI: 10.7759/cureus.36408.Peer-Reviewed Original ResearchLow-grade gliomasIntracranial tumorsPersonality changesTreatment of LGGCentral nervous system tumorsMain presenting featuresBroad differential diagnosisNervous system tumorsPresenting featuresPediatric patientsCase reportSystem tumorsFavorable outcomeEndocrine conditionsMain symptomsDifferential diagnosisIntracranial neoplasmsBrain tumorsGrade gliomasEarly identificationSymptomsTumorsOlder childrenCommon typeNatural language processing tools
2022
Spectrum of qualitative and quantitative imaging of pilomyxoid, intermediate pilomyxoid and pilocytic astrocytomas in relation to their genetic alterations
Fadel SA, von Reppert M, Kazarian E, Omay EZE, Marks A, Linder N, Hoffmann KT, Darbinyan A, Huttner A, Aboian MS. Spectrum of qualitative and quantitative imaging of pilomyxoid, intermediate pilomyxoid and pilocytic astrocytomas in relation to their genetic alterations. Neuroradiology 2022, 65: 195-205. PMID: 35984480, DOI: 10.1007/s00234-022-03027-3.Peer-Reviewed Original ResearchConceptsPilocytic astrocytomaImaging characteristicsADC valuesAggressive imaging characteristicsSuprasellar pilocytic astrocytomaRecurrence/progressionPediatric brain tumorsFrontal white matterWhole-exome sequencingPilomyxoid astrocytomaIntraventricular extensionSuprasellar regionThird ventriclePosterior fossaAtypical locationBrain tumorsWhite matterGrade 1TumorsAstrocytomasDriver mutationsExome sequencingGenetic alterationsPatientsHippocampus
2018
Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib
Marks AM, Bindra RS, DiLuna ML, Huttner A, Jairam V, Kahle KT, Kieran MW. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. Pediatric Blood & Cancer 2018, 65: e26969. PMID: 29380516, DOI: 10.1002/pbc.26969.Peer-Reviewed Original ResearchConceptsAnaplastic gangliogliomaBRAF/MEK inhibitor combinationsBRAF V600ESubsequent tumor responseDabrafenib/trametinibLarge clinical trialsSquamous cell carcinomaMEK inhibitor combinationsSignificant side effectsSignificant skin reactionsCell carcinomaCase reportSkin reactionsTumor responseClinical trialsBrain tumorsInhibitor combinationsSide effectsAdolescent femalesGangliogliomaTrametinibPrevious reactionsV600EMonotherapyRash
2012
A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy
Marks AM, Packer RJ. A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy. Seminars In Pediatric Neurology 2012, 19: 43-48. PMID: 22641075, DOI: 10.1016/j.spen.2012.02.015.Peer-Reviewed Original ResearchConceptsCentral nervous system tumorsSecondary central nervous system tumorsNervous system tumorsPediatric malignanciesSystem tumorsPrimary brain tumorsRole of treatmentCancer predisposition syndromeTreatment of leukemiaSecondary malignanciesSecondary tumorsBrain tumorsPredisposition syndromeMalignancyTumorsTreatmentRemarkable stridesSyndromeEtiologyLeukemiaIncidenceDiagnosis